Top Industry Leaders in the Lung Cancer Market
Latest Lung Cancer Therapeutics Companies Update:
AstraZeneca's Tagrisso shows promising results in a Phase III trial: This trial demonstrated Tagrisso's efficacy in treating EGFR-mutated non-small cell lung cancer (NSCLC) with less brain metastases compared to other targeted therapies.
Mirati Therapeutics' investigational drug adavosertib receives Breakthrough Therapy designation from the FDA: This designation recognizes the potential of adavosertib for treating KRAS G12C-mutated NSCLC, a previously difficult-to-treat mutation.
Roche acquires Blueprint Medicines for $3.9 billion: This acquisition strengthens Roche's lung cancer portfolio by adding Blueprint's expertise in targeted therapies for RET-driven cancers, including some lung cancers.
Merck & Co. partners with BeiGene to develop and commercialize tislelizumab: This collaboration expands access to tislelizumab, a promising PD-1 inhibitor, for treating lung cancer and other solid tumors worldwide.
List of Lung Cancer Therapeutics Key companies in the market
- Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Pfizer (U.S.)
- Bristol-Myers Squibb (U.S.)
- Eli Lilly and Company (U.S.)
- Sanofi (France)